The Genetics of Severe Asthma in Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01238432|
Recruitment Status : Active, not recruiting
First Posted : November 10, 2010
Last Update Posted : June 23, 2020
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||The Genetics of Severe Asthma in Children|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||April 2025|
|Estimated Study Completion Date :||April 2025|
Children with asthma who are admitted to the hospital with an exacerbation.
Children with asthma who have not been admitted to the hospital with an exacerbation.
Children without asthma or any other chronic condition.
- The primary end point is the development of a near fatal asthma exacerbation. [ Time Frame: 3 years ]
- The secondary end point is hospital length of stay. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01238432
|United States, Connecticut|
|Connecticut Children's Medical Center|
|Hartford, Connecticut, United States, 06103|
|Principal Investigator:||Christopher L Carroll, MD, MS||Connecticut Children's Medical Center|